Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn’s Disease to Prevent Loss of Response

[1] Targan SR(1997)A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease N Engl J Med 337 1029-1035

[2] Hanauer SB(2002)Maintenance infliximab for Crohn’s diseasee: the ACCENT I randomized trial Lancet 359 1541-1549

[3] van Deventer SJ(2007)A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn’s disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone J Clin Gastroenterol 41 677-681

[4] Hanauer SB(2009)Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in CD Inflamm Bowel Dis 15 1295-1301

[5] Fegan BG(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[6] Lichtenstein GR(2010)Infliximab, azathioprine, or combination therapy for Crohn’s disease N Engl J Med 15 1383-1395

[7] Bhatia JK(2009)Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update J Pediatr Gastroenterol Nutr 48 386-388

[8] Korelitz BI(2006)Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial Aliment Pharmacol Ther 24 1333-1400

[9] Panagopoulos G(2006)Effect of concurrent elemental diet on infliximab treatment for Crohn’s disease J Gastroenterol Hepatol 21 1143-1149

[10] Schnitzler F(2013)Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults Dig Dis Sci 58 1329-1334

[1] Targan SR(1997)A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease N Engl J Med 337 1029-1035

[2] Hanauer SB(2002)Maintenance infliximab for Crohn’s diseasee: the ACCENT I randomized trial Lancet 359 1541-1549

[3] van Deventer SJ(2007)A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn’s disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone J Clin Gastroenterol 41 677-681

[4] Hanauer SB(2009)Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in CD Inflamm Bowel Dis 15 1295-1301

[5] Fegan BG(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[6] Lichtenstein GR(2010)Infliximab, azathioprine, or combination therapy for Crohn’s disease N Engl J Med 15 1383-1395

[7] Bhatia JK(2009)Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update J Pediatr Gastroenterol Nutr 48 386-388

[8] Korelitz BI(2006)Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial Aliment Pharmacol Ther 24 1333-1400

[9] Panagopoulos G(2006)Effect of concurrent elemental diet on infliximab treatment for Crohn’s disease J Gastroenterol Hepatol 21 1143-1149

[10] Schnitzler F(2013)Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults Dig Dis Sci 58 1329-1334